LifeSci Acquisition in a definitive proxy filing set a Dec. 22 meeting for shareholders to vote on the SPAC’s proposed merger with Vincera Pharma. The combined company is expected to have approximately $60 million in cash at closing if shareholders approve the deal. LifeSCi said as of Dec. 3 there was approximately $65.7 million held in trust. Read more.
Related Posts
Colonnade Acquisition II Outlines $480M Plastiq Deal in Prelim Proxy
Plastiq is expected to add approximately $320 million to its balance sheet, assuming no Colonnade shareholder redemptions.
Constellation Acquisition I Sponsor Loans SPAC up to $73.6K
The SPAC's focus is on targets “at the forefront of change in one of several rapidly changing segments of the global economy,.
Property Solutions Acquisition II Files for $250M IPO
The proptech-focused SPAC will target technology companies that service the real estate industry.
HL Sets Fusion Fuel Vote
The HL shareholder vote on the proposed business combination with Fusion Fuel Green is Dec. 4.